Welcome to our dedicated page for Ironwood news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood stock.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) is a biotechnology company focused on gastrointestinal (GI) and rare diseases, and its news flow reflects this specialization. Investors and followers of IRWD news will see regular updates on the performance and clinical development of its key assets, particularly LINZESS® (linaclotide) and apraglutide.
News about LINZESS often covers U.S. net sales, prescription demand trends based on IQVIA data, and changes in financial guidance related to collaboration revenue and adjusted EBITDA. Ironwood and its U.S. partner AbbVie share equally in U.S. brand collaboration profits, so quarterly and full-year results frequently highlight LINZESS commercial margin, net profit for the U.S. brand collaboration, and the impact of pricing dynamics, gross-to-net rebate reserves and healthcare policy changes.
For apraglutide, Ironwood’s news includes clinical and regulatory milestones in short bowel syndrome with intestinal failure (SBS-IF). Press releases describe data from the STARS Phase 3 trial and the STARS Extend long-term extension study, including the number of apraglutide-dosed patients achieving enteral autonomy, as well as feedback from the U.S. Food and Drug Administration on the need for a confirmatory Phase 3 trial. Updates on the timing and design of this confirmatory trial and on regulatory submissions are recurring themes.
IRWD news also covers financial guidance for LINZESS U.S. net sales, total revenue and adjusted EBITDA, along with restructuring activities, cost management efforts and strategic reorganization steps. Additional announcements address topics such as Nasdaq listing notifications, changes in the company’s independent registered public accounting firm, participation in investor and scientific conferences, and the ongoing review of strategic alternatives with financial advisors.
By following this IRWD news page, readers can track how Ironwood’s GI and rare disease programs progress over time, how financial expectations evolve, and how regulatory, commercial and strategic developments may influence the company’s outlook.
Ironwood Pharmaceuticals (Nasdaq: IRWD), a leader in gastrointestinal healthcare, announced that CEO Tom McCourt will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 9:00 a.m. PT in San Francisco, CA. The live audio webcast can be accessed via the company's website, with a replay available for 14 days post-conference. Ironwood is renowned for its work on LINZESS®, a top medication for treating IBS-C and CIC. The company continues to innovate in GI treatments and aims to redefine care standards for patients.
Ironwood Pharmaceuticals (Nasdaq: IRWD) will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 4:30 p.m. ET in New York. The event will be accessible via a live webcast on Ironwood's website, where a replay will also be available for 14 days post-conference. Located in Boston, Massachusetts, Ironwood specializes in gastrointestinal healthcare, notably for conditions like IBS-C and CIC, led by its flagship product LINZESS.
Ironwood Pharmaceuticals reported a strong Q3 2022, with a 10% year-over-year increase in LINZESS prescription demand, reaching over 1 million prescriptions in a quarter for the first time. The company plans to submit a supplemental New Drug Application (sNDA) to the FDA for LINZESS in pediatric patients by the end of 2022. Financial highlights include a GAAP net income of $50 million and adjusted EBITDA of $69 million. Ironwood maintains its guidance for 2022, expecting total revenue between $420 million and $430 million.
Ironwood Pharmaceuticals (Nasdaq: IRWD) will host its third quarter 2022 investor update conference call on November 3, 2022, at 8:30 a.m. ET. Participants can join by calling (888) 330-2384 for U.S. and Canada or (240) 789-2701 internationally, using conference ID 4671230. A replay will be available starting the same day at 11:30 a.m. ET until November 17, 2022. The archived webcast will be accessible on Ironwood’s website for 14 days post-call. Ironwood focuses on advancing gastroenterological treatments, especially for IBS-C and CIC.
Ironwood Pharmaceuticals announced positive topline results from a Phase III trial of linaclotide in pediatric patients aged 6-17 with functional constipation (FC). The study met its primary and secondary endpoints, demonstrating significant improvements in spontaneous bowel movements and stool consistency compared to placebo. Linaclotide was generally well-tolerated, with diarrhea being the most common side effect. There are currently no FDA approved pediatric treatments for FC, affecting 4-6 million children in the U.S. Ironwood and partner AbbVie may file for a supplemental New Drug Application (sNDA).
Ironwood Pharmaceuticals (Nasdaq: IRWD) will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference scheduled for September 8, 2022, at 8:00 a.m. ET in Everett, MA. A live webcast will be available on the company's website, with a replay accessible for 14 days post-conference. Ironwood is renowned for its gastrointestinal healthcare focus, particularly with LINZESS®, a leading treatment for IBS-C and CIC. Founded in 1998 and headquartered in Boston, Massachusetts, Ironwood aims to redefine GI care.
Ironwood Pharmaceuticals reported its Q2 2022 results, showcasing a 9% year-over-year growth in LINZESS prescription demand. Despite this, total revenues decreased to $97.2 million from $104.0 million in Q2 2021, with GAAP net income dropping significantly to $37 million from $391 million. The company completed its share repurchase program and repaid $120.7 million in convertible notes. Ironwood reiterated its guidance for 2022, projecting low single-digit U.S. LINZESS net sales growth and total revenue between $420 million and $430 million.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announces an investor update conference call on August 4, 2022, at 8:30 a.m. ET. Participants can join by calling (888) 330-2384 (U.S.) or (240) 789-2701 (international) with conference ID 4671230. The call will be recorded and available for replay starting at 11:30 a.m. ET the same day until August 18, 2022. Ironwood specializes in gastrointestinal healthcare, particularly with its LINZESS® treatment for IBS-C and CIC. More details can be found on their website.
Ironwood Pharmaceuticals (Nasdaq: IRWD) presented new findings at the 2022 Digestive Disease Week that suggest IW-3300 could manage abdominal pain in patients with disorders of gut-brain interaction. Current Phase I trials aim to explore this compound's potential for visceral pain conditions, including interstitial cystitis and endometriosis. The company also shared insights on the efficacy of linaclotide in treating IBS-C and functional constipation in pediatric patients, aiming to address the unmet needs in gastrointestinal diseases.
Ironwood Pharmaceuticals (Nasdaq: IRWD) will showcase eight studies, including two oral presentations, at the Digestive Disease Week 2022 conference in San Diego from May 21 to May 24. One key study focuses on IW-3300's effect on chronic pelvic pain, while another analyzes linaclotide's impact on abdominal symptoms in IBS-C patients. CEO Tom McCourt will receive the ASGE President’s Award for his contributions to gastrointestinal endoscopy, highlighting Ironwood's ongoing commitment to GI health advancements.